See Graham's ranking
1.0
Solventum Corp. operates in the “other” sector, within the medical and technological products industry, formed from the spin-off of 3M’s healthcare division.
The company was created to establish an independent operation focused on medical solutions, consolidating a portfolio centered on innovation, safety, and clinical efficiency. Strategic partnerships with research institutions and sector-related companies support the development of healthcare technologies.
The company’s portfolio includes medical devices, dental materials, infection control technologies, filtration systems, and hospital management software. Its solutions are used by hospitals, clinics, and laboratories, focusing on process optimization and patient safety.
Continuous investment in research and development enables the company to keep pace with regulatory requirements and evolving healthcare demands.
With global operations, Solventum maintains a strong presence in North America, Europe, and Asia, distributing its products through an integrated worldwide network.
The market in which it operates is highly competitive, influenced by strict regulation, technological advances, and increasing digitalization of medical services. The company responds to these challenges by modernizing its processes, developing new technologies, and improving operational efficiency.
Its organizational structure includes research centers, manufacturing facilities, and commercial offices located in key regions. Technologies such as artificial intelligence, hospital automation, and data analytics guide product development and strengthen the integration between medical devices and clinical systems.
With approximately 22,000 employees, Solventum adopts a business model based on the sale of medical equipment, recurring supply contracts, and complementary services. The company’s shares are traded on Nasdaq under the ticker SOLV.
History and When Solventum Corp. Was Founded
Solventum Corp. was founded in 2024 in the United States as a result of the spin-off of 3M’s healthcare division. The process was announced in 2022, aiming to create a more focused strategy for medical solutions amid growing global demand for healthcare technology and hospital digitalization.
In its early years, the company concentrated on establishing its independent operational structure, ensuring continuity of the portfolio previously managed by 3M.
The transition required developing autonomous processes, expanding production capacity, and strengthening commercial operations to ensure stability and administrative independence.
A significant milestone in the company’s trajectory was its initial public offering (IPO) on Nasdaq in 2024, which expanded its investment capacity and supported the growth of projects related to medical technology.
Between 2024 and the subsequent years, Solventum advanced in research initiatives, automation, and digital integration, consolidating itself as an independent company dedicated to high-performance medical solutions aligned with global healthcare transformations.
Additional Information
The Company BASF SE ADR (United States), is listed on Nasdaq with a market cap of $ 45.27 Billions, having an equity of $ 39.81 Billions.
The Company is listedthe in the sector of Others and categorized in industry of Others.
In the last 12 months the Company had a revenue of $ 70.42 Billions, which generated a profit in the amount of $ 343.47 Millions.
As for its main indicators, the Company has a P/E ratio of 131.79, a P/BV ratio of 1.14 and in the last 12 months the dividend yield of BASFY was at 4.97%.
The Company is traded internationally through the ticker BASFY.
